Vasostrict

Do not take it if

Quoted from the official label, section “Contraindications”.

How to take it

These directions are for this exact strength and form. Another one is different.

• Dilute 20 units/mL single dose vial or 200 units/10 mL (20 units/mL) multiple dose vial contents with normal saline (0.9% sodium chloride) or 5% dextrose in water (D5W) to either 0.1 units/mL or 1 unit/mL for intravenous administration.
• Discard unused diluted solution after 18 hours at room temperature or 24 hours under refrigeration.
• ( 2.1 ) The 20 units/100 mL, 40 units/100 mL, 60 units/100 mL and 50 units/50 mL single dose vials do not require further dilution prior to administration.
• ( 2.1 ) Post-cardiotomy shock:
• 0.03 to 0.1 units/minute ( 2.2 ) Septic shock:
• 0.01 to 0.07 units/minute ( 2.2 )
• 2.1 Preparation of Solution Inspect parenteral drug products for particulate matter and discoloration prior to use, whenever solution and container permit.
• Vasostrict ® Solution for Dilution, 20 units/mL and 200 units/10 mL (20 units/mL) Dilute Vasostrict ® in normal saline (0.9% sodium chloride) or 5% dextrose in water (D5W) prior to use for intravenous administration.
• Discard unused diluted solution after 18 hours at room temperature or 24 hours under refrigeration.
• Table 1 Preparation of diluted solutions Fluid restriction? Final concentration Mix Vasostrict ® Diluent No 0.1 units/mL 2.5 mL (50 units) 500 mL Yes 1 unit/mL 5 mL (100 units) 100 mL Vasostrict ® Premixed Solution, 20 units/100 mL (0.2 units/mL), 40 units/100 mL (0.4 units/mL), 60 units/100 mL (0.6 units/mL) and 50 units/50 mL (1 unit/mL) This product does not require further dilution prior to administration.
• 2.2 Administration In general, titrate to the lowest dose compatible with a clinically acceptable response.
• The recommended starting dose is:
• Post-cardiotomy shock:
• 0.03 units/minute Septic Shock:
• 0.01 units/minute Titrate up by 0.005 units/minute at 10- to 15-minute intervals until the target blood pressure is reached.
• There are limited data for doses above 0.1 units/minute for post-cardiotomy shock and 0.07 units/minute for septic shock.
• Adverse reactions are expected to increase with higher doses.
• After target blood pressure has been maintained for 8 hours without the use of catecholamines, taper vasopressin injection by 0.005 units/minute every hour as tolerated to maintain target blood pressure.

Quoted from the official label, section “Dosage & Administration”.

Other warnings

Quoted from the official label, section “Warnings”.

Pregnancy and breastfeeding

Quoted from the official label, section “OTC — Pregnancy or Breast Feeding”.

Other medicines

Quoted from the official label, section “Drug Interactions”.

If you take too much

In an emergency, call your local emergency number or a poison control centre.

Quoted from the official label, section “Overdosage”.

Use in children

Safety and effectiveness of Vasostrict ® in pediatric patients with vasodilatory shock have not been established.

Quoted from the official label, section “Pediatric Use”.

Use in older people

• Clinical studies of vasopressin did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.
• Other reported clinical experience has not identified differences in responses between the elderly and younger patients.
• In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy [see Warnings and Precautions (5) , Adverse Reactions (6) , and Clinical Pharmacology (12.3) ] .

Quoted from the official label, section “Geriatric Use”.

Side effects

• The following adverse reactions associated with the use of vasopressin were identified in the literature.
• Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to estimate their frequency reliably or to establish a causal relationship to drug exposure.
• Bleeding/lymphatic system disorders:
• Hemorrhagic shock, decreased platelets, intractable bleeding Cardiac disorders:
• Right heart failure, atrial fibrillation, bradycardia, myocardial ischemia Gastrointestinal disorders:
• Mesenteric ischemia Hepatobiliary:
• Increased bilirubin levels Renal/urinary disorders:
• Acute renal insufficiency Vascular disorders:
• Distal limb ischemia Metabolic:
• Hyponatremia Skin:
• Ischemic lesions Postmarketing Experience Reversible diabetes insipidus [see Warnings and Precautions (5.2) ] The most common adverse reactions include decreased cardiac output, bradycardia, tachyarrhythmias, hyponatremia and ischemia (coronary, mesenteric, skin, digital).
• ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Par Health at 1-800-828-9393 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Quoted from the official label, section “Adverse Reactions”.

Strengths and forms

• FORMS AND STRENGTHS Injection:
• vasopressin injection, USP is a clear, practically colorless solution available as:
• 20 units/mL in a single dose vial.
• To be used after dilution. 200 units/10 mL (20 units/mL) in a multiple dose vial.
• To be used after dilution. 20 units/100 mL (0.2 units/mL) premixed in dextrose in a single dose vial.
• Ready to use. 40 units/100 mL (0.4 units/mL) premixed in dextrose in a single dose vial.
• Ready to use. 60 units/100 mL (0.6 units/mL) premixed in dextrose in a single dose vial.
• Ready to use. 50 units/50 mL (1 unit/mL) premixed in dextrose in a single dose vial.
• Ready to use.
• Injection: 20 units/mL in a single dose vial.
• To be used after dilution. 200 units/10 mL (20 units/mL) in a multiple dose vial.
• To be used after dilution. 20 units/100 mL (0.2 units/mL) premixed in dextrose in a single dose vial.
• Ready to use. 40 units/100 mL (0.4 units/mL) premixed in dextrose in a single dose vial.
• Ready to use. 60 units/100 mL (0.6 units/mL) premixed in dextrose in a single dose vial.
• Ready to use. 50 units/50 mL (1 unit/mL) premixed in dextrose in a single dose vial.
• Ready to use.

Quoted from the official label, section “Dosage Forms & Strengths”.

What it looks like and how it is packed

• Vasostrict ® (vasopressin injection, USP) is a clear, practically colorless solution for intravenous administration available as:
• NDC 42023-164-10:
• A carton of 10 single dose vials.
• Each vial contains vasopressin 1 mL at 20 units/mL.
• NDC 42023-164-25: A carton of 25 single dose vials.
• Each vial contains vasopressin 1 mL at 20 units/mL.
• NDC 42023-190-01: A carton of 1 multiple dose vial.
• Each vial contains vasopressin 10 mL at 200 units/10 mL (20 units/mL).
• NDC 42023-219-10: A carton of 10 single dose vials.
• Each vial contains vasopressin premixed in dextrose 100 mL at 40 units/100 mL (0.4 units/mL).
• NDC 42023-220-10: A carton of 10 single dose vials.
• Each vial contains vasopressin premixed in dextrose 100 mL at 60 units/100 mL (0.6 units/mL).
• NDC 42023-237-10: A carton of 10 single dose vials.
• Each vial contains vasopressin premixed in dextrose 100 mL at 20 units/100 mL (0.2 units/mL).
• NDC 42023-268-10: A carton of 10 single dose vials.
• Each vial contains vasopressin premixed in dextrose 50 mL at 50 units/50 mL (1 unit/mL).
• Store between 2°C and 8°C (36°F and 46°F).
• Do not freeze.
• Vials may be held up to 12 months upon removal from refrigeration to room temperature storage conditions (20°C to 25°C [68°F to 77°F], USP Controlled Room Temperature), anytime within the labeled shelf life.
• Once removed from refrigeration, unopened vial should be marked to indicate the revised 12 month expiration date.
• If the manufacturer’s original expiration date is shorter than the revised expiration date, then the shorter date must be used.
• Do not use Vasostrict ® beyond the manufacturer’s expiration date stamped on the vial.
• After initial entry into the 10 mL vial, the remaining contents must be refrigerated.
• Discard the refrigerated 10 mL vial after 30 days after first puncture.
• The storage conditions and expiration periods are summarized in the following table.
• Unopened Refrigerated 2°C to 8°C (36°F to 46°F) Unopened Room Temperature 20°C to 25°C (68°F to 77°F) Do not store above 25°C (77°F) Opened (After First Puncture) 1 mL Vial Until manufacturer expiration date 12 months or until manufacturer expiration date, whichever is earlier N/A 10 mL Vial Until manufacturer expiration date 12 months or until manufacturer expiration date, whichever is earlier 30 days 50 mL Vial Until manufacturer expiration date 12 months or until manufacturer expiration date, whichever is earlier N/A 100 mL Vial Until manufacturer expiration date 12 months or until manufacturer expiration date, whichever is earlier N/A

Quoted from the official label, section “How Supplied”.

How to store it

• Store between 2°C and 8°C (36°F and 46°F).
• Do not freeze.
• Vials may be held up to 12 months upon removal from refrigeration to room temperature storage conditions (20°C to 25°C [68°F to 77°F], USP Controlled Room Temperature), anytime within the labeled shelf life.
• Once removed from refrigeration, unopened vial should be marked to indicate the revised 12 month expiration date.
• If the manufacturer’s original expiration date is shorter than the revised expiration date, then the shorter date must be used.
• Do not use Vasostrict ® beyond the manufacturer’s expiration date stamped on the vial.
• After initial entry into the 10 mL vial, the remaining contents must be refrigerated.
• Discard the refrigerated 10 mL vial after 30 days after first puncture.
• The storage conditions and expiration periods are summarized in the following table.
• Unopened Refrigerated 2°C to 8°C (36°F to 46°F) Unopened Room Temperature 20°C to 25°C (68°F to 77°F) Do not store above 25°C (77°F) Opened (After First Puncture) 1 mL Vial Until manufacturer expiration date 12 months or until manufacturer expiration date, whichever is earlier N/A 10 mL Vial Until manufacturer expiration date 12 months or until manufacturer expiration date, whichever is earlier 30 days 50 mL Vial Until manufacturer expiration date 12 months or until manufacturer expiration date, whichever is earlier N/A 100 mL Vial Until manufacturer expiration date 12 months or until manufacturer expiration date, whichever is earlier N/A

Quoted from the official label, section “Storage and Handling”.

What is in it

• Vasopressin is a polypeptide hormone.
• Vasostrict ® is a sterile, aqueous solution of synthetic arginine vasopressin for intravenous administration.
• The 1 mL solution contains vasopressin 20 units/mL, 1.36 mg sodium acetate buffer and Water for Injection, USP.
• The 10 mL solution contains vasopressin 20 units/mL, 1.36 mg sodium acetate buffer, chlorobutanol, NF 0.5% as a preservative and Water for Injection, USP.
• Sodium hydroxide and hydrochloric acid are included to adjust to a pH of 3.8.
• The 50 mL solution contains vasopressin 1 unit/mL.
• Each mL of the 1 unit/mL strength also contains dextrose anhydrous, 0.0546 mg acetic acid, 0.012 mg sodium acetate and Water for Injection, USP.
• Sodium hydroxide and hydrochloric acid are included to adjust to a pH of 3.8.
• The 100 mL solution contains vasopressin 0.2 units/mL, 0.4 units/mL, or 0.6 units/mL.
• Each mL of the 0.2 unit/mL strength also contains dextrose anhydrous, 0.0546 mg acetic acid, 0.012 mg sodium acetate and Water for Injection, USP.
• Each mL of the 0.4 unit/mL strength also contains dextrose anhydrous, 0.0546 mg acetic acid, 0.012 mg sodium acetate and Water for Injection, USP.
• Each mL of the 0.6 unit/mL strength also contains dextrose anhydrous, 0.0546 mg acetic acid, 0.012 mg sodium acetate and Water for Injection, USP.
• Sodium hydroxide and hydrochloric acid are included to adjust to a pH of 3.8.
• Each vial of the Vasostrict ® premixed solutions contains 5% Dextrose in approximately 100 mL Water for Injection.
• The chemical name of vasopressin is Cyclo (1-6) L-Cysteinyl-L-Tyrosyl-L-Phenylalanyl-L-Glutaminyl-L-Asparaginyl-L-Cysteinyl-L-Prolyl-L-Arginyl-L-Glycinamide.
• It is a white to off-white amorphous powder, freely soluble in water.
• The structural formula is: Molecular Formula: C 46 H 65 N 15 O 12 S 2 Molecular Weight:
• 1084.23 One mg is equivalent to 530 units.
• Chemical Structure

Quoted from the official label, section “Description”.

Ingredients people check for

Lactose, gluten, dyes, sugars and other ingredients that matter with an allergy, intolerance or diet — as this product’s FDA label lists them.

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

Details

Source: NDC Directory · 2026-09-13 · not reviewed by a clinician

Source: US Food and Drug Administration, NDC Directory. Reuse terms: US government work (FDA).

Report wrong or outdated information on this page

Other strengths and forms

5 products are sold under this name. Grouped by form; a number on a strength means several companies make it.

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.

See every product with Vasopressin